CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a significant B-cell lymphoid malignancy.
• Novel therapeutic strategies are needed for DLBCL patients refractory to conventional chemotherapy.
• Pleiotropic pathway modifiers, like CC-122, are emerging as promising agents.

Purpose of the Study:

• To evaluate the immunomodulatory effects and efficacy of CC-122 in patients with DLBCL.
• To investigate the impact of CC-122 on immune cell subsets and activity.
• To explore CC-122 as a potential treatment for refractory DLBCL.

Main Methods:

• Phase I clinical trial (NCT01421524) involving three patients.
• Assessment of immunomodulatory effects of CC-122.
• Analysis of immune cell phenotypes, including NK cells, myeloid-derived suppressor cells, and Tregs.
• Monitoring of T cell activation via co-stimulatory molecule CD28.

Main Results:

• CC-122 demonstrated immunomodulatory effects in DLBCL patients.
• Observed regulation of NK cell phenotype and activity.
• Reduced accumulation of myeloid-derived suppressor cells and Tregs.
• Delayed activation of T cells through CD28 co-stimulatory molecule.

Conclusions:

• CC-122 exhibits potential as an immunomodulatory agent in DLBCL.
• The compound may re-regulate immune responses by reducing suppressive cells and enhancing T cell activity.
• CC-122 presents a potential alternative therapeutic option for DLBCL patients resistant to standard chemotherapy.